Previous studies have proven that the expression of PD-L1 and the presence of tumor-infiltrating lymphocytes (TILs) within TME are considered prognostic and predictive markers in patients treated with immunotherapy (62, 63). The gene discussed is CD274; the disease is neoplasm.